AstraZeneca Hopes Danicopan Interim Data Will Prove Sufficient For NDA Filing

 
• By Joseph Haas

Danicopan seen as potential add-on therapy for paroxysmal nocturnal hemoglobinuria patients getting suboptimal results from Soliris or Ultomiris therapy. AstraZeneca will investigate filing for approval on 12-week data.

Hemolysis
AstraZeneca thinks danicopan can provided added benefit for some PNH patients • Source: Shutterstock

More from Clinical Trials

More from R&D